| __timestamp | Alkermes plc | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 104381000 |
| Thursday, January 1, 2015 | 4019000 | 100171000 |
| Friday, January 1, 2016 | 2301000 | 102726000 |
| Sunday, January 1, 2017 | 7232000 | 96171000 |
| Monday, January 1, 2018 | 68895000 | 66449000 |
| Tuesday, January 1, 2019 | 52816000 | 42672000 |
| Wednesday, January 1, 2020 | 1946000 | 42534000 |
| Friday, January 1, 2021 | 1020000 | 53311000 |
| Saturday, January 1, 2022 | 393842000 | 82258000 |
| Sunday, January 1, 2023 | 270806000 | 118011000 |
| Monday, January 1, 2024 | 245326000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and Celldex Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Celldex consistently allocated a significant portion of its resources to R&D, peaking in 2023 with an impressive 118% increase from its 2014 spending. In contrast, Alkermes showed a more volatile pattern, with a dramatic surge in 2022, marking a 5,000% increase from its 2014 expenditure. This fluctuation highlights Alkermes' strategic shifts in innovation priorities. As the biotech landscape continues to evolve, these spending patterns offer valuable insights into each company's long-term vision and commitment to pioneering advancements.
Research and Development: Comparing Key Metrics for Pfizer Inc. and Celldex Therapeutics, Inc.
R&D Spending Showdown: GSK plc vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Alkermes plc
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and Veracyte, Inc.
R&D Insights: How Alkermes plc and ImmunityBio, Inc. Allocate Funds
R&D Spending Showdown: Alkermes plc vs Ligand Pharmaceuticals Incorporated
Alkermes plc vs Novavax, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Alkermes plc vs Evotec SE
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and Taro Pharmaceutical Industries Ltd.
Galapagos NV vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Celldex Therapeutics, Inc. vs Novavax, Inc.